Abstract | INTRODUCTION: A reduction of testicular volume (TV) represents an important clinical sign, which may hide sperm abnormalities and predispose to hypogonadism. AIM: METHODS: In this 1-year-long prospective design, patients with abnormal sperm parameters, mild reduction in TV (8-12 mL) and normal gonadotropin, and total testosterone (TT) serum levels were recruited in this study. Patients treated for 4 months with urofollitropin were included in group A, those treated with intracytoplasmatic sperm injection due to a female-factor infertility were included in group B. Hormone values, sperm parameters, and TV were detected at baseline (T0), after 4 (T1) and 12 months (T2) in group A and at T0 and T2 in group B. RESULTS: Group A (n = 80) showed increased follicle-stimulating hormone (FSH) at T1 and sperm morphology at T1 and T2 compared to T0 (all p < 0.05). Group B (n = 50) had lower TT and higher FSH levels at T2 compared to T0 (all p < 0.05). At T2, TT, VT, total sperm count, progressive motility, total motility, and sperm morphology were higher in group A compared to group B (all p < 0.05). CONCLUSION:
|
Authors | Sandro La Vignera, Rosita A Condorelli, Rossella Cannarella, Laura Cimino, Laura Mongioi', Ylenia Duca, Filippo Giacone, Aldo E Calogero |
Journal | Endocrine
(Endocrine)
Vol. 66
Issue 2
Pg. 381-385
(11 2019)
ISSN: 1559-0100 [Electronic] United States |
PMID | 31240459
(Publication Type: Journal Article)
|
Chemical References |
- Urofollitropin
- Testosterone
- Luteinizing Hormone
- Follicle Stimulating Hormone
|
Topics |
- Adult
- Follicle Stimulating Hormone
(blood)
- Humans
- Infertility, Male
(blood, diagnostic imaging, drug therapy)
- Longitudinal Studies
- Luteinizing Hormone
(blood)
- Male
- Organ Size
- Prospective Studies
- Sperm Count
- Sperm Motility
(drug effects)
- Spermatozoa
(drug effects)
- Testis
(diagnostic imaging)
- Testosterone
(blood)
- Ultrasonography
- Urofollitropin
(administration & dosage, therapeutic use)
|